Is Fezonatant marketed in China

Fizolinant is a non-hormonal drug targeting moderate to severe vasomotor symptoms caused by menopause. It is developed by Japan's Astellas Pharmaceuticals and its trade name is Veozah. The drug was approved by the US FDA for marketing in May 2023 and was approved in the European Union in December of the same year. Currently, Fezonatant has not been marketed in China, nor is it included in the national medical insurance.

Is filazonatant available on the domestic market?

As a new non-hormonal NK3 receptor antagonist, its domestic launch has attracted much attention. At present, the drug has not yet been approved by China’s drug regulatory authorities, so the original drug cannot be purchased through formal domestic channels.

Domestic marketing status

The original drug of Fezonatan is produced by Astellas Pharmaceuticals of Japan, with the trade name Veozah. Although the drug is already available in European and American markets, China has not yet approved its entry into the domestic market. This means that patients cannot purchase original drugs through hospitals or regular pharmacies.

Circulation of generic drugs

There are already generic drugs in circulation on the market, such as the Laos Lucius version of the generic version of Fezolnetam. These generic drugs are often obtained through cross-border medical channels. Patients should be careful to identify the authenticity of medicines when purchasing and avoid purchasing inferior or counterfeit products.

The domestic launch of fezonatant still needs to wait for the completion of the relevant approval process. If approved in the future, it will provide more treatment options for menopausal women.

Is filazonatant easy to buy?

Since filazonatant has not yet been officially launched in China, it is difficult to purchase the original drug. But the emergence of generic drugs has provided an alternative for some patients.

Purchasing Channels for Original Drugs

Original drugs are currently mainly purchased through overseas channels, such as the US or EU markets. Patients can obtain it through formal cross-border medical service institutions, but the price is higher and transportation and storage conditions need to be paid attention to.

How to purchase generic drugs

The price of generic drugs in Lucius, Laos is relatively low, but you need to choose reliable channels when purchasing. It is recommended to purchase through qualified medical service institutions to avoid health risks caused by drug quality issues.

Purchasing Precautions

When purchasing Fezonastat, you need to pay attention to the production date, packaging integrity and manufacturer information of the drug. At the same time, it is recommended to use it under the guidance of a doctor to avoid adverse reactions caused by self-medication.

Although generic drugs provide convenience to some patients, you still need to be cautious when purchasing to ensure that the source of the drugs is legal.

Is filzonaitant included in the national medical insurance list?

Felazonatan is currently not included in China’s national medical insurance directory, which is directly related to its lack of listing in the country.

Current status of medical insurance coverage

Since Fezonastat has not been approved for marketing in China, it is naturally unable to enter the scope of medical insurance reimbursement. If patients need to use it, they need to purchase it in full at their own expense, which imposes a heavy financial burden.

Possibility of being included in medical insurance in the future

If filazonatant passes domestic approval and is launched on the market in the future, its possibility of being included in medical insurance will depend on the clinical value of the drug, the outcome of price negotiations and other factors.

Alternative treatment options

For the treatment of menopausal symptoms, other drugs and therapies are available in China, and some of them have been included in medical insurance. Patients can choose a suitable treatment plan under the guidance of a doctor.

The issue of medical insurance coverage of fezonatant still needs to wait for further policy adjustments after its launch in China. Until then, patients need to weigh their medication options based on their own circumstances.